{"result": "(\"entity\"<|>ALEXANDER EK<|>PERSON<|>Alexander EK is one of the authors of the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.)\n##\n(\"entity\"<|>PEARCE EN<|>PERSON<|>Pearce EN is one of the authors of the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.)\n##\n(\"entity\"<|>BRENT GA<|>PERSON<|>Brent GA is one of the authors of the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.)\n##\n(\"entity\"<|>BROWN RS<|>PERSON<|>Brown RS is one of the authors of the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.)\n##\n(\"entity\"<|>CHEN H<|>PERSON<|>Chen H is one of the authors of the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.)\n##\n(\"entity\"<|>DOSIOU C<|>PERSON<|>Dosiou C is one of the authors of the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.)\n##\n(\"entity\"<|>ANDERSEN SL<|>PERSON<|>Andersen SL is one of the authors of the study on the severity of birth defects after propylthiouracil exposure in early pregnancy.)\n##\n(\"entity\"<|>OLSEN J<|>PERSON<|>Olsen J is one of the authors of the study on the severity of birth defects after propylthiouracil exposure in early pregnancy.)\n##\n(\"entity\"<|>WU CS<|>PERSON<|>Wu CS is one of the authors of the study on the severity of birth defects after propylthiouracil exposure in early pregnancy.)\n##\n(\"entity\"<|>LAURBERG P<|>PERSON<|>Laurberg P is one of the authors of the study on the severity of birth defects after propylthiouracil exposure in early pregnancy.)\n##\n(\"entity\"<|>MARTINO E<|>PERSON<|>Martino E is one of the authors of the studies on the effects of amiodarone on thyroid function.)\n##\n(\"entity\"<|>MAMMOLI C<|>PERSON<|>Mammoli C is one of the authors of the studies on the in vitro cytotoxic effect of amiodarone.)\n##\n(\"entity\"<|>YOSHIHARA A<|>PERSON<|>Yoshihara A is one of the authors of the study on the treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy.)\n##\n(\"entity\"<|>NOH J<|>PERSON<|>Noh J is one of the authors of the study on the treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy.)\n##\n(\"entity\"<|>YAMAGUCHI T<|>PERSON<|>Yamaguchi T is one of the authors of the study on the treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy.)\n##\n(\"entity\"<|>OHYE H<|>PERSON<|>Ohye H is one of the authors of the study on the treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy.)\n##\n(\"entity\"<|>SATO S<|>PERSON<|>Sato S is one of the authors of the study on the treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy.)\n##\n(\"entity\"<|>SEKIYA K<|>PERSON<|>Sekiya K is one of the authors of the study on the treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy.)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>ALEXANDER EK<|>Alexander EK contributed to the guidelines published by the American Thyroid Association<|>7)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>PEARCE EN<|>Pearce EN contributed to the guidelines published by the American Thyroid Association<|>7)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>BRENT GA<|>Brent GA contributed to the guidelines published by the American Thyroid Association<|>7)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>BROWN RS<|>Brown RS contributed to the guidelines published by the American Thyroid Association<|>7)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>CHEN H<|>Chen H contributed to the guidelines published by the American Thyroid Association<|>7)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>DOSIOU C<|>Dosiou C contributed to the guidelines published by the American Thyroid Association<|>7)\n##\n(\"relationship\"<|>ANDERSEN SL<|>AMERICAN THYROID ASSOCIATION<|>Andersen SL's study on birth defects is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>OLSEN J<|>AMERICAN THYROID ASSOCIATION<|>Olsen J's study on birth defects is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>WU CS<|>AMERICAN THYROID ASSOCIATION<|>Wu CS's study on birth defects is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>LAURBERG P<|>AMERICAN THYROID ASSOCIATION<|>Laurberg P's study on birth defects is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>MARTINO E<|>AMIODARONE<|>Martino E's studies on amiodarone are significant in understanding its effects on thyroid function<|>8)\n##\n(\"relationship\"<|>MAMMOLI C<|>AMIODARONE<|>Mammoli C's studies on amiodarone are significant in understanding its effects on thyroid function<|>8)\n##\n(\"relationship\"<|>YOSHIHARA A<|>AMERICAN THYROID ASSOCIATION<|>Yoshihara A's study on Graves’ disease is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>NOH J<|>AMERICAN THYROID ASSOCIATION<|>Noh J's study on Graves’ disease is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>YAMAGUCHI T<|>AMERICAN THYROID ASSOCIATION<|>Yamaguchi T's study on Graves’ disease is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>OHYE H<|>AMERICAN THYROID ASSOCIATION<|>Ohye H's study on Graves’ disease is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>SATO S<|>AMERICAN THYROID ASSOCIATION<|>Sato S's study on Graves’ disease is referenced in the guidelines by the American Thyroid Association<|>6)\n##\n(\"relationship\"<|>SEKIYA K<|>AMERICAN THYROID ASSOCIATION<|>Sekiya K's study on Graves’ disease is referenced in the guidelines by the American Thyroid Association<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: arona puede             inducir    efectos     si-\n         berían ser trasferidos a PTU tan pronto fuera posible. A partir de la semana 16 no hay evidencia                                                                 milares al hipotiroidismo a nivel tisular, que puede estar relacionado con una reducción en\n         ni a favor ni en contra de mantener el PTU o volver al tiamazol, por lo que no establecen ningu-                                                                 el número de receptores catecolamínicos. No se conocen los mecanismos moleculares de\n         na recomendación al respecto (opción D falsa).                                                                                                                   estas acciones antagonistas de la amiodarona sobre los efectos de las hormonas tiroideas,\n         Referencias:                                                                                                                                                     pero podrían estar relacionados con una downregulation de los receptores a hormonas tiroi-\n         • Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and                deas causado por           la amiodarona) (opción D).\n           Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27:315-89.\n         • Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid.                                En consecuencia, la respuesta correcta a esta pregunta es la C.\n           2014;24:1533-40.\n         • Anderson SL, Olsen J, Laurberg P. Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab.                                   Referencias:\n           2016;101:1606-14.                                                                                                                                              • Chiovato L, Martino E, Tonacchera M, Santini F, Lapi P, Mammoli C, et al. Studies on the in vitro cytotoxic effect of amiodarone.\n         • Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking                                Endocrinology. 1994;134:2277-82.\n           methimazole. J Clin Endocrinol Metab. 2000;85:3233-8.                                                                                                          • Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997;126:63-73.\n         • Johansen K, Andersen AN, Kampmann JP, Mølholm Hansen JM, Mortensen HB. Excretion of methimazole in human milk. Eur J Clin                                      • Martino E, Aghini-Lombardi F, Bartalena L, Grasso L, Loviselli A, Velluzzi F, et al. Enhanced susceptibility to amiodarone-induced\n           Pharmacol. 1982;23:339-41.                                                                                                                                       hypothyroidism in patients with thyroid autoimmune disease. Arch Intern Med. 1994;154:2722-6.\n         • Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001;86:2354-9.                                        • Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22:240-54.\n         • Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, et al. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy      • Pitsiavas V, Smerdely P, Li M, Boyages SC. Amiodarone induces a different pattern of ultrastructural change in the thyroid to iodine\n           and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396-403.                                                                        excess alone in both the BB/W rat and the Wistar rat. Eur J Endocrinol. 1997;137:89-98.\n                                                                                                                                                                          • Trip MD, Wiersinga WM, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroi-\n                                                                                                                                                                            dism. Am J Med. 1991;91:507-11.\n\n\n\n     20  Señale      la afirmación falsa           en relación       con el tratamiento con amiodarona:\n         A.  Puede producir hipo- o hipertiroidismo.                                                                                                                  21  Elija la afirmación falsa:\n         B.  Puede tener efecto tóxico sobre las células foliculares tiroideas.                                                                                           A.  El tiamazol y el carbimazol pueden tener efectos teratogénicos.\n         C.  La disfunción tiroidea producida desaparece de forma inmediata tras la suspensión                                                                            B.  El hipertiroidismo suele empeorar durante el tercer trimestre de gestación.\n             del tratamiento.                                                                                                                                             C.  El propiltiuracilo (PTU) es más hepatotóxico que el tiamazol.\n         D.  Puede bloquear competitivamente la unión de la T3 a su receptor nuclear.                                                                                     D.  La presencia de TSI (inmunoglobulinas estimulantes del tiroides) en\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AMIODARONE<|>ORGANIZATION<|>Amiodarone is a medication that can induce hypothyroidism or hyperthyroidism and has toxic effects on thyroid follicular cells.)\n##\n(\"entity\"<|>PROPYLTHIOURACIL<|>ORGANIZATION<|>Propylthiouracil (PTU) is an antithyroid drug that may have hepatotoxic effects and is used during pregnancy.)\n##\n(\"entity\"<|>THYROID DISEASE<|>EVENT<|>Thyroid disease refers to various conditions affecting the thyroid gland, including hypothyroidism and hyperthyroidism, which can be influenced by medications like amiodarone and PTU.)\n##\n(\"entity\"<|>TIAMAZOL<|>ORGANIZATION<|>Tiamazol is an antithyroid medication that can have teratogenic effects and is used to treat hyperthyroidism.)\n##\n(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association provides guidelines for the diagnosis and management of thyroid disease during pregnancy and postpartum.)\n##\n(\"entity\"<|>HYPOTHYROIDISM<|>EVENT<|>Hypothyroidism is a condition characterized by an underactive thyroid gland, which can be induced by medications like amiodarone.)\n##\n(\"entity\"<|>HYPERTIROIDISM<|>EVENT<|>Hyperthyroidism is a condition characterized by an overactive thyroid gland, which can also be influenced by medications such as amiodarone.)\n##\n(\"relationship\"<|>AMIODARONE<|>HYPOTHYROIDISM<|>Amiodarone can induce hypothyroidism as a side effect of its use<|>8)\n##\n(\"relationship\"<|>AMIODARONE<|>HYPERTIROIDISM<|>Amiodarone can also induce hyperthyroidism as a side effect of its use<|>8)\n##\n(\"relationship\"<|>PROPYLTHIOURACIL<|>HYPOTHYROIDISM<|>Propylthiouracil is used to manage thyroid disease, including hypothyroidism<|>6)\n##\n(\"relationship\"<|>TIAMAZOL<|>HYPERTIROIDISM<|>Tiamazol is used to treat hyperthyroidism<|>7)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>THYROID DISEASE<|>The American Thyroid Association provides guidelines for the management of thyroid disease<|>9)\n##\n(\"relationship\"<|>AMIODARONE<|>TIAMAZOL<|>Both amiodarone and tiamazol are related to the treatment and management of thyroid conditions<|>5)\n<|COMPLETE|>"}]}